litlas
Log inCreate account

Petros Grivas

Active 2011–2025

190
Papers
21,681
Citations
59
h-index
176
i10-index

Citations

Citations per year for Petros Grivas2001: 1 citations2007: 1 citations2009: 7 citations2012: 5 citations2014: 4 citations2015: 7 citations2016: 59 citations2017: 204 citations2018: 255 citations2019: 600 citations2020: 1,024 citations2021: 1,374 citations2022: 1,083 citations2023: 861 citations2024: 1,496 citations2025: 765 citations2026: 21 citations2002–2006: no citations, so these years are not shown2008: no citations, so this year is not shown2010–2011: no citations, so these years are not shown2013: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,472 citing papers, 23.8% of this breakdownChina: 1,160 citing papers, 11.2% of this breakdownItaly: 661 citing papers, 6.4% of this breakdownUnited Kingdom: 630 citing papers, 6.1% of this breakdownFrance: 504 citing papers, 4.9% of this breakdownGermany: 480 citing papers, 4.6% of this breakdownSpain: 443 citing papers, 4.3% of this breakdownCanada: 379 citing papers, 3.6% of this breakdownJapan: 337 citing papers, 3.2% of this breakdownNetherlands: 275 citing papers, 2.6% of this breakdownSwitzerland: 242 citing papers, 2.3% of this breakdownSouth Korea: 218 citing papers, 2.1% of this breakdown
0%23.8%Other 24.9%

Institutions

Fields

  • Medicine80.9%
  • Biochemistry, Genetics and Molecular Biology12.5%
  • Immunology and Microbiology3.6%
  • Engineering0.9%
  • Computer Science0.3%
  • Materials Science0.2%
  • Other1.6%

Topics

  • Cancer Immunotherapy and Biomarkers14.6%
  • Bladder and Urothelial Cancer Treatments10%
  • Urinary and Genital Oncology Studies4.6%
  • Cancer Genomics and Diagnostics3.5%
  • Immunotherapy and Immune Responses3.3%
  • COVID-19 and healthcare impacts3.3%
  • Other60.7%

Coauthors

All papers

Open in search
  1. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Authors: Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas - New England Journal of Medicine 2020 cited by 1,479

  2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Authors: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 cited by 3,714

  3. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    Authors: Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211

  4. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

    Authors: Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Romain Banchereau, Bernadett Szabados, Kobe Yuen, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Maurizio Perdicchio, Jingbin Zhang, David S. Shames, Viraj Degaonkar, Xiaodong Shen, Corey Carter, Carlos Bais, Joaquim Bellmunt, Sanjeev Mariathasan - Nature 2021 cited by 629

  5. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    Authors: Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas - Journal of Clinical Oncology 2021 cited by 533

  6. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

    Authors: Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, M. Roumiguié, Laurence E. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Ronald de Wit - The Lancet Oncology 2021 cited by 533

  7. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    Authors: Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R. Plimack, Noah M. Hahn, Ronald de Wit, Lei Pang, Mary J. Savage, Rodolfo F. Perini, Stephen J. O’Keefe, Dean F. Bajorin, Joaquim Bellmunt - The Lancet Oncology 2017 cited by 1,342

  8. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    Authors: Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H. O’Donnell, Jonathan E. Rosenberg, Daniel M. Geynisman, Daniel P. Petrylak, Jean Hoffman‐Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S. van der Heijden, Cora N. Sternberg, Nicole N. Davarpanah, Thomas Powles - The Lancet Oncology 2021 cited by 412

  9. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

    Authors: Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros Grivas - Journal of Clinical Oncology 2023 cited by 211

  10. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

    Authors: Faisal Fa’ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H. Johnson, Chrystia M. Zobniw, Van Anh Trinh, Muhammad O. Awiwi, Nourel Hoda Tahon, Khaled M. Elsayes, Kaysia Ludford, Emma J. Montazari, Julia Chernis, Maya Dimitrova, Sabina Sandigursky, Jeffrey A. Sparks, Osama Abu-Shawer, Osama E. Rahma, Uma Thanarajasingam, Ashley M. Zeman, Rafee Talukder, Namrata Singh, Sarah H. Chung, Petros Grivas, May Daher, Ala Abudayyeh, Iman Osman, Jeffrey S. Weber, Jean Tayar, María E. Suarez‐Almazor, Noha Abdel‐Wahab, Adi Diab - Journal for ImmunoTherapy of Cancer 2023 cited by 95

  11. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

    Authors: Thomas Powles, Zoe J. Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Himanshu Sethi, Alexey Aleshin, Yi Shi, Nicole N. Davarpanah, Corey Carter, Joaquim Bellmunt, Sanjeev Mariathasan - European Urology 2023 cited by 131

  12. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

    Authors: Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Savage, Xiao Fang, James Luke Godwin, Tara L. Frenkl, Blanca Homet Moreno, Ronald de Wit, Elizabeth R. Plimack - Journal of Clinical Oncology 2020 cited by 292

  13. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

    Authors: Kendal Jensen, Eric Q. Konnick, Michael T. Schweizer, Alexandra Sokolova, Petros Grivas, Heather H. Cheng, Nola Klemfuss, Mallory Beightol, Evan Y. Yu, Peter S. Nelson, Bruce Montgomery, Colin C. Pritchard - JAMA Oncology 2020 cited by 158

  14. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

    Authors: Vadim S. Koshkin, Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam, Christopher Su, Ali Raza Khaki, Chelsea K. Osterman, Michael Glover, Ryan S. Chiang, Dimitrios Makrakis, Rafee Talukder, Emily Lemke, T. Anders Olsen, Jayanshu Jain, Albert Jang, Alicia Ali, Tanya Jindal, Jonathan Chou, Terence W. Friedlander, Christopher Hoimes, Arnab Basu, Yousef Zakharia, Pedro C. Barata, Mehmet Asım Bilen, Hamid Emamekhoo, Nancy B. Davis, Sumit Shah, Matthew I. Milowsky, Shilpa Gupta, Matthew T. Campbell, Petros Grivas, Guru Sonpavde, Deepak Kilari, Ajjai Alva - Cancer 2021 cited by 85

  15. Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective

    Authors: Jeremy Yuen‐Chun Teoh, Ashish M. Kamat, Peter C. Black, Petros Grivas, Shahrokh F. Shariat, Marek Babjuk - Nature Reviews Urology 2022 cited by 196

  16. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    Authors: Arjun Vasant Balar, Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Andrea Necchi, Daniel P. Petrylak, Elizabeth R. Plimack, Jin Xu, Kazuo Imai, Blanca Homet Moreno, Joaquim Bellmunt, Ronald de Wit, Peter H. O’Donnell - Annals of Oncology 2022 cited by 114

  17. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

    Authors: Petros Grivas, Damien Pouessel, Chandler H. Park, Philippe Barthélémy, Manojkumar Bupathi, Daniel P. Petrylak, Neeraj Agarwal, Sumati Gupta, Aude Fléchon, Chethan Ramamurthy, Nancy B. Davis, Alejandro Recio‐Boiles, Cora N. Sternberg, Astha Bhatia, Cabilia Pichardo, Mitch Sierecki, Julia Tonelli, Huafeng Zhou, Scott T. Tagawa, Yohann Loriot - Journal of Clinical Oncology 2024 cited by 75

  18. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

    Authors: John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, Alexander M. Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John A. Thompson, Michel Obéid - Journal for ImmunoTherapy of Cancer 2020 cited by 167

  19. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

    Authors: Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery R. Reichert, Joseph W. Kim, Mehmet Asım Bilen, Bradley A. McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel P. Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan W.C. Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, Jonathan E. Rosenberg - New England Journal of Medicine 2024 cited by 145

  20. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

    Authors: Thomas Powles, Srikala S. Sridhar, Yohann Loriot, Joaquim Bellmunt, Xinmeng Jasmine Mu, Keith A. Ching, Jie Pu, Cora N. Sternberg, Daniel P. Petrylak, Rosa Tambaro, Louis Marie Dourthe, Carlos Álvarez-Fernández, Maureen J.B. Aarts, Alessandra di Pietro, Petros Grivas, Craig B. Davis - Nature Medicine 2021 cited by 115

  21. Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types

    Authors: Răzvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, Andrew Albright, Julie Kobie, Lingkang Huang, Qing Zhao, Anran Wang, Hua Ma, Zheng Cao, Michael Morrissey, Antoni Ribas, Petros Grivas, David W. Cescon, Terrill K. McClanahan, Alexandra Snyder, Mark Ayers, Jared Lunceford, Andrey Loboda - Clinical Cancer Research 2021 cited by 74

  22. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

    Authors: Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, Chih–Yuan Hsu, Aakash Desai, Gilberto Lopes, Petros Grivas, Corrie Painter, Solange Peters, Michael A Thompson, Ziad Bakouny, Gerald Batist, Tanios Bekaii‐Saab, Mehmet Asım Bilen, Nathaniel Bouganim, Mateo Bover Larroya, Daniel Castellano, Salvatore A. Del Prete, Deborah B. Doroshow, Pamela Egan, Arielle Elkrief, Dimitrios Farmakiotis, Daniel Flora, Matthew D. Galsky, Michael Glover, Elizabeth A. Griffiths, Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Þorvarður R. Hálfdánarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali Raza Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry L. Reynolds, L Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit Shah, Justin Shaya, John A. Steinharter, Keith Stockerl‐Goldstein, Suki Subbiah, Donald C. Vinh, Firas Wehbe, Lisa B. Weissmann, Julie Wu, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Albert C. Yeh, Peter Paul Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian I. Rini, Jeremy L. Warner, Maheen Z. Abidi, Jared D. Acoba, Neeraj Agarwal, Syed A. Ahmad, Archana Ajmera, Jessica K. Altman, Anne H. Angevine, Nilo Azad, Michael Bär, Aditya Bardia, Jill S. Barnholtz‐Sloan, Briana Barrow, Babar Bashir, Rimma Belenkaya, Stephanie Berg, Eric Bernicker, Christine M. Bestvina, Rohit Bishnoi, Genevieve M. Boland, Mark Bonnen, Gabrielle Bouchard, Daniel W. Bowles, Fiona Busser, Angelo Cabal, Paolo F. Caimi, Theresa M. Carducci, Carla Casulo and 136 more - The Lancet 2020 cited by 1,802

  23. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

    Authors: John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, Alexander M. Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John A. Thompson, Michel Obéid - Annals of Oncology 2020 cited by 231

  24. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

    Authors: Yohann Loriot, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip L. Palmbos, Arjun Vasant Balar, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, M. Sierecki, Hao Zhou, Petros Grivas, Philippe Barthélémy, Scott T. Tagawa - Annals of Oncology 2024 cited by 82